SERBIAN MEDICAL SOCIETY
ONCOLOGY SECTION

UMSTBS SECTION OF
NURSES IN ONCOLOGY

61ST ONCOLOGY CONGRESS

BELGRADE | SERBIA

37TH SYMPOSIUM OF ONCOLOGY NURSES-TECHNICIANS OF SERBIA

18TH FORUM FOR CANCER PATIENTS

NOVEMBER 13–16th 2024 • SAVA CENTER • BELGRADE, SERBIA

61st ONCOLOGY CONGRESS

13–16th November 2024
Sava Center, Belgrade, Serbia

Congress organizer

Serbian Medical Society Oncology Section
Address: Džordža Vašingtona 19, 11000 Belgrade, Serbia
Telephone: +381 11 3234-450
E-mail: sldrustvo@gmail.com (office)
kanceroloskasekcijasld@gmail.com (office)

President of the Oncology Section and Congress President
Professor dr Ivan Marković
ivanmarkovic66@yahoo.com

Secretary of the Oncology Section and Congress Secretary
Assistant prof. dr Nada Santrač
santrac.nada@gmail.com

Congress co-organizers

Institute for Oncology and Radiology of Serbia

Serbian Society of Surgical Oncology

Serbian Society of Medical Oncology

Serbian Association for Cancer Research

International endorsement

European Society of Surgical Oncology – Congress endorsement

European Society of Endocrine Surgery – Thyroid Cancer Masterclass endorsement

Executive organizer

NOVI ASTAKOS
Palmotićeva 18B, 11000 Belgrade, Serbia
Telephone: +381 63 337 808, +381 63 232 663
congress@astakos.com
www.astakos.com

Dear colleagues,

It is with great pleasure that we announce the **61st Oncology Congress**, organized by the **Serbian Medical Society Oncology Section**, to be held on **November 13 to 16 2024**, in a brand new part of the **Sava Center**, in Belgrade, Serbia.

Traditionally, the **scientific program** is rich, diverse and multidisciplinary, covering wide range of topics within a four-day congress, focusing on innovations in the diagnosis and treatment of breast cancer, lung cancer, digestive oncology, skin melanoma, endometrial cancer, head and neck tumors and lymphomas.

The Scientific Committee has organized two **special panels** on cancer screening and access to oncology treatments in Serbia, as well as three **specialized masterclasses** on **Early Breast Cancer: multidisciplinary approach, Lung Cancer and Thyroid Cancer** that will be available to all participants. The special **ESSO Young Surgeons Alumni Club (EYSAC) Research Academy Workshop** will provide our young oncology professionals with a unique opportunity to gain essential research skills and dive into the power of RedCap for data analysis, while this year's **Patients' forum** will focus on the role of cancer patients associations in screening.

Traditionally, in the spirit of multidisciplinarity and team work, **nurses and technicians of Serbian oncology institutions** are organizing their **37th Symposium** that will be held on **November 15 and 16th 2024.**


As one of the oncology congresses with the longest tradition, with diverse, multidisciplinary scientific program and speakers of great international impact, we are proud to say that our congress has once again received **endorsement by the European Society of Surgical Oncology (ESSO),** while our **Thyroid Cancer Masterclass** was endorsed by **European Society of Endocrine Surgery (ESES).**

Thank you for your constant support and for being part of our **joined mission** to improve patients' care and outcomes by constantly improving our knowledge and skills, because together we can **reshape the future of oncology in Serbia and region**.

Welcome!



Professor dr Ivan Marković
Serbian Medical Society Oncology Section President
61st Oncology Congress President



Assistant prof. dr Nada Santrač
Serbian Medical Society Oncology Section Secretary
61st Oncology Congress Secretary

61st ONCOLOGY CONGRESS

13–16th November 2024
Sava Center, Belgrade, Serbia

Congress President
Scientific Committee Chair

Ivan Marković

Congress Secretary
Organizing Committee Chair

Nada Santrač

Scientific and Organizing Committee

Ivan Marković
Nada Santrač
Davorin Radosavljević
Ljiljana Stamatović
Milan Žegarac
Snežana Šušnjar
Marijana Milović Kovačević
Ivana Božović Spasojević
Lazar Popović
Joseph Gligorov (France)
Wim Ceelen (Belgium)
Dara Lundon (New York, USA)
Kyriakos Vamvakidis (Greece)
Srđan Nikolić
Suzana Stojanović Rundić
Marija Ristić
Marina Nikitović
Tatjana Stanojković
Suzana Matković
Radmila Janković
Milena Čavić
Ana Krivokuća
Ana Jovićević
Mirjan Nadrljanski
Jovica Milovanović
Tamara Ursulović
Jelena Spasić
Bojan Zarić
Mila Purić
Snežana Bošnjak

61st ONCOLOGY CONGRESS

13–16th November 2024

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 1, November 13th 2024, WEDNESDAY

HALL A	
09:00–10:00	**Congress opening**
10:00-10:30	**Plenary lecture** **Harnessing Social Media for Oncology in the Modern Era** **Gilberto Morgan, OncoAlert 360**
10:30–10:45	Q&A, moderators Ivan Marković & Nada Santrač
10:45–12:00	**Special panel** **Access to oncology treatments in Serbia** Moderator: Lazar Popović Panelists: Ferenc Vicko (Ministry of Health), Sanja Radojević Škodrić (Republic Fund of Health Insurance), Jelena Drulović (Central Committee for Drugs), Bojan Trkulja (INOVIA), Milan Žegarac (Institute for Oncology and Radiology of Serbia), Zoran Radovanović (Institute for Oncology Vojvodina), Joseph Gligorov (France), Savo Pilipović (Serbian Association of Patients)
12:00–13:00	Lunch
13:00	**Breast Cancer Masterclass** **Early Breast Cancer – multidisciplinary approach** Organizers: Ivan Marković, Marijana Milović Kovačević, Nada Santrač
13:00–13:45	**Breast Cancer Masterclass – part 1** **Introduction** Moderators: Ivan Marković, Marijana Milović Kovačević, Nada Santrač
13:05–13:25	Modern concept of early breast cancer treatment — Joseph Gligorov
13:25–13:45	Panel discussion: Ferenc Vicko, Simona Borštnar, Jeliazko Arabadjiev, Tatjana Ivković Kapicl, Dragana Đilas, Ana Krivokuća
13:45–14:15	**Breast Cancer Masterclass – part 2** **Pathology in early breast cancer** Moderators: Tatjana Ivković Kapicl, Marijana Milović Kovačević

13:45–14:00	Optimization of analysis and pathology reporting	Tatjana Ivković Kapicl
14:00–14:15	Panel discussion: Maja Jovičić Milentijević, Irena Jovanić, Duško Dunđerović	
14:15–14:45	**Breast Cancer Masterclass – part 3** **Diagnostics in early breast cancer** Moderators: Mirjan Nadrljanski, Marko Spasić	
14:15–14:30	Optimization of initial staging in early breast cancer	Mirjan Nadrljanski
14:30–14:45	Panel discussion: Jasmina Bajrović, Marijana Basta Nikolić, Dejan Dimitrijević, Ivana Minić	
14:45–15:15	**Sponsored symposium 1** **ROCHE** **Pathways to Progress: Innovations and Strategies in Cancer Elimination and Patient Care** Accelerating the elimination of cervical cancer in Serbia: Achievements, challenges and the way forward – Verica Jovanović From Lab to Clinic: Cutting-Edge Technologies Shaping Patient Care – Branka Zukić	
15:15-15:30	Coffee break	
15:30–16:20	**Breast Cancer Masterclass – part 4** **Surgery in early breast cancer** Moderators: Ivan Marković, Nada Santrač	
15:30–15:50	Surgical recommendations in early breast cancer in the setting of modern systemic treatments	Nikola Rocco
15:50–16:20	Panel discussion: Marko Buta, Marko Spasić, Marijana Milović Kovačević, Viktorija Vučaj Ćirilović, Tatjana Ivković Kapicl, Olivera Ivanov	
16:20–16:50	**Sponsored symposium 2** **ASTRAZENECA** **The LYNX Journey: Translating OlympiA evidence into clinical practice** Moderator: Ivana Minić Panelists: Ana Cvetanović, Ivana Kolarov Bjelobrk, Ana Krivokuća	
16:50–17:00	Coffee break	
17:00–18:30	**Breast Cancer Masterclass – part 5** **Systemic treatments in early breast cancer** Moderators: Marijana Milović Kovačević, Jeliazko Arabadjiev	
17:00–17:15	Systemic treatment of HR+ early breast cancer	Ana Cvetanović
17:15–17:30	Panel discussion: Ivana Minić, Zdenka Gojković, Marko Jevrić, Aleksandar Ranković, Irena Jovanić, Dragana Bogdanović Stojanović	

17:30–17:45	Systemic treatment of HER2+ early breast cancer	Jeliazko Arabadjiev
17:45–18:00	Panel discussion: Ivana Minić, Semir Bešlija, Marko Spasić, Neda Milosavljević, Irena Jovanić, Dragana Bogdanović Stojanović	
18:00–18:15	Systemic treatment of TNBC early breast cancer	Lazar Popović
18:15–18:30	Panel discussion: Ivana Minić, Sanja Lekić, Vladimir Selaković, Olivera Ivanov, Duško Dunđerović, Ana Krivokuća	
18:30–19:05	**Breast Cancer Masterclass – part 6** **Radiotherapy in early breast cancer** Moderators: Jasmina Mladenović, Olivera Ivanov	
18:30–18:45	Escalation and de-escalation of adjuvant radiotherapy in early breast cancer	Aleksandar Ranković
18:45–19:05	Panel discussion: Neda Milosavljević, Milica Radić, Mersid Ćorović, Vladimir Selaković	
19:05–19:15	**Masterclass conclusions** Ivan Marković, Marijana Milović Kovačević, Nada Santrač	
19:30	**Welcome cocktail, Sava Centar Exhibition Hall**	
	HALL B	
10:30–12:00	**Scientific session 1** **Human papillomavirus-associated head and neck malignancies** Moderators: Tamara Ursulović, Jovica Milovanović	
10:30–10:40	Human papillomavirus and vaccination	Ana Jovićević
10:40–10:50	Morphological characteristics and classification of HPV-associated head and neck malignancies	Nada Tomanović
10:50–11:00	Role of surgery in treatment of HPV-associated head and neck malignancies	Miljan Folić
11:00–11:10	Role of radiotherapy in treatment of HPV-associated head and neck malignancies	Nataša Jovanović Korda
11:10–11:20	Systemic treatment of HPV-associated head and neck malignancies	Lenche Kostadinova
11:20–11:30	Perioperative nutrition support in patients with head and neck tumors	Tjaša Ivošević
11:30–12:00	Discussion and conclusions	
12:00–13:00	Lunch	

13:00–14:15	**Scientific session 2** **New perspectives in lymphoma treatment** Moderators: Mila Purić, Lazar Popović	
13:00–13:15	Hodgkin lymphoma	Maja Popović
13:15–13:30	Follicular and mantle-cell lymphoma	Ivan Petković
13:30–13:45	Diffuse B large-cell lymphoma	Anastasios Stathis
13:45–14:15	Panel discussion: Snježana Bogićević, Nebojša Petrović, speakers	
14:15–15:00	Break	
15:00–16:40	**Scientific session 3** **Artificial intelligence in cancer imaging** Moderators: Ružica Maksimović, Nadica Miljković, Mirjan Nadrljanski	
15:00–15:15	Artificial intelligence in breast imaging – possible solutions in clinical practice	Mirjan Nadrljanski
15:15–15:30	Artificial intelligence in mammography – from pilot project to clinical practice	Dubravko Ćulibrk
15:30–15:45	Advantages and challenges in the application of machine and deep learning in medicine	Nadica Miljković
15:45–16:00	Artificial intelligence in the assessment of colorectal cancer tumor response to neoadjuvant chemotherapy	Mladen Marinković
16:00–16:15	Public health aspects of the application of artificial intelligence in the prevention and early detection of oncological diseases	Bosiljka Đikanović
16:15–16:30	Application of artificial intelligence in the modern concept of imaging	Ružica Maksimović
16:30–16:40	Conclusions	
16:40–16:45	Break	
16:45–17:45	**Scientific session 4** **Adverse effects of immune checkpoint inhibitors: a multidisciplinary approach** Moderator: Snežana Bošnjak, Snežana Šušnjar	
	Introduction	Snežana Šušnjar
16:45–17:00	Skin toxicity as an adverse effect of immunotherapy	Feđa Đorđević
17:00–17:15	Colitis as an adverse effect of immunotherapy	Jelena Dimitrijević

17:15–17:30	Endocrine side effects of immunotherapy	Snežana Šušnjar Dimitrije Đurđević
17:30–17:45	Q&A, discussion	
17:45–18:15	**Sponsored symposium 1** **SANDOZ** **What does Ziextenzo®, pegfilgrastim from Sandoz, bring us in clinical practice** Recommendations for the use of granulocyte colony growth factor (G-CSF) – Snežana Šušnjar Ziextenzo® in clinical practice: usage, doubts and misconceptions – Jelena Dimitrijević	
19:30	**Welcome cocktail, Sava Centar Exhibition Hall**	
	HALL C	
17:30–19:30	**PATIENTS' FORUM** **Role of cancer patients associations in screening** Moderators: Ana Jovićević, Svetlana Berat	
17:30–17:45	Cancer epidemiology in Serbia	Dragana Jovićević
17:45–18:00	Cancer screening programs in Serbia	Radoljupka Radosavljević
18:00–18:15	Perspectives for screening projects in Serbia	Jelena Janković
18:15–18:30	Role of patients' associations in screening in Slovenia	Tanja Španić
18:30–18:45	Results of the research on the characteristics of the population that conducted FOBT testing in Serbia	Bosiljka Đikanović
18:45–19:00	Results of the survey lead by patients' association „Milica“	Vesna Bondžić
19:00–19:15	Role of patients' association in cervical cancer prevention	Gorica Đokić
19:15–19:30	Q&A, discussion, conclusions	
19:30	**Welcome cocktail, Sava Centar Exhibition Hall**	

61st ONCOLOGY CONGRESS

13–16th November 2024

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 2, November 14th 2024, THURSDAY

	HALL A	
08:00–09:15	**Special panel** **Cancer prevention and screening in Serbia – how can we do better?** Moderators: Ivan Marković, Ana Jovićević	
08:00–08:15	European Cancer Organization (ECO) screening activities and strategy for the future	Wim Ceelen, ECO
08:15–08:25	Cancer epidemiology in Serbia	Ana Jovićević (IORS)
08:25–09:15	Panel discussion: Ferenc Vicko (Ministry of Health), Verica Jovanović (Institute of Public Health "Dr Milan Jovanovic Batut"), Simona Borštnar (Slovenia), Tanja Španić (Europa Donna Slovenia)	
09:15–09:30	Coffee break	
09:30–10:30	**Scientific session 1** **Systemic treatment of breast cancer: novelties and dilemmas – part 1: HER2-positive breast cancer** Moderators: Ljiljana Stamatović, Natalija Dedić Plavetić	
09:30–09:50	HER2+ breast cancer systemic treatment	Javier Cortes
09:50–10:30	Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger	
10:30–10:45	Coffee break	
10:45–11:50	**Scientific session 2** **Systemic treatment of breast cancer: novelties and dilemmas – part 2: HR-positive/HER2-negative breast cancer** Moderators: Simona Borštnar, Snežana Šušnjar	
10:45–11:05	Adjuvant chemotherapy for ER+ breast cancer: advances and a critical overview of therapy de-escalation	Otto Metzger
11:05-11:50	Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger	
11:50–12:10	Coffee break	

12:10–13:10	**Scientific session 3** **Systemic treatment of breast cancer: novelties and dilemmas – part 3: Triple negative breast cancer** Moderators: Ivana Božović Spasojević, Lazar Popović
12:10–12:30	Triple negative breast cancer systemic treatment — Ivana Božović Spasojević
12:30–13:10	Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger
13:10–14:10	**Sponsored symposium 1** **ROCHE** **Stepping Into The Spotlight: The Goal Is Cure.** Revolution and Evolution of Therapy for Patients with HER2+ Breast Cancer (video material) Welcome and Introduction – Ivana Božović Spasojević Sharing HEReNA story – Ivana Božović Spasojević, Marijana Milović Kovačević, Lazar Popović Raising the bar for HER – PHERGain trial – Javier Cortes Panel discussion: Rewriting HER story – All participants Closing remarks – Ivana Božović Spasojević
14:10–15:10	Lunch
15:10–15:40	**Sponsored symposium 2** **ASTRAZENECA** **Change is coming: Enhertu will write HER Destiny** Moderator: Ivana Božović Spasojević Panelists: Lazar Popović, Natalija Dedić Plavetić, Simona Borštnar
15:40–16:25	**Sponsored symposium 3** **NOVARTIS** **Evolution of HR+/HER2-breast cancer clinical practice** Moderator: Lazar Popović Speakers: Marijana Milović Kovačević, Ana Cvetanović
16:30–16:45	Coffee break
16:45–18:15	**Sponsored symposium 4** **ELI LILLY** **Expert Discussion on the CDK4/6i Choices in MBC & EBC** Opening words from moderator - Lazar Popović Conducting Risk Assessment to Identify Patients with High-Risk HR+, HER2- EBC. Evolving Standards and Current Guidance – Marijana Milović Kovačević TREATMENT PARADIGM FOR HR+HER2- BREAST CANCER – Joseph Gligorov Managing Adverse Events and Improving Adherence/Persistence in High-Risk HR+, HER2- EBC – Snežana Šušnjar Analyzing the Latest Evidence on CDK4/6 Inhibitors in HR+, HER2- MB - Lazar Popović Panel discussion – all

18:15–19:00	**Sponsored symposium 5** **PFIZER** **Are we (RWE) ready? Discussion among experts** Moderator: Lazar Popović Speakers: Lazar Popović, Sonja Martinović Šalinger, Ivana Božović, Ana Cvetanović	
	HALL B	
08:00–08:30	**Sponsored symposium 1** **Johnson & Johnson** **How to achieve better tretment outcomes for patients with EGFR exon20ins mNSCLC?** Why do we need novel therapies in EGFR exon20ins NSCLC? – Davorin Radosavljević Clinical study PAPILLON and CHRYSALIS – efficacy data – Bojan Zarić EGFR & MET dual inhibition – safety profile of bispecific antibody – Milica Kontić-Jovanović Panel discussion: Davorin Radosavljević, Bojan Zarić, Milica Kontić-Jovanović	
08:30–13:30	**Lung Cancer Masterclass** Organizers: Davorin Radosavljević, Bojan Zarić, Jelena Spasić	
08:30–09:15	**Lung Cancer Masterclass – part 1** **Screening and early detection** Moderators: Marko Jakopović, Goran Stojanović	
08:30–08:45	Intro: Why should Lung Cancer screening be implemented?	Vladimir Stojšić
08:45–08:55	Hot topic: Real world data – Croatian experience	Marko Jakopović
08:55–09:15	Panel discussion: Rafal Dziadziuszko, Marko Jakopović, Davorin Radosavljević, Goran Stojanović, Bojan Zarić	
09:15–10:30	**Lung Cancer Masterclass – part 2** **Advances in early stage non oncogene-addicted NSCLC** Moderators: Davorin Radosavljević, Marko Jakopović	
09:15–09:25	Intro: Moving therapy into early stage	Feđa Đorđević
09:25–09:40	New end-points in early-stage clinical trials	Jelena Spasić
09:40–10:00	Decision-making process in early stage non-oncogene addicted NSCLC: neoadjuvant vs. adjuvant vs. perioperative?	Sanjay Popat
10:00–10:15	Stage III beyond PACIFIC	Bojan Zarić
10:15–10:30	Panel discussion: Sanjay Popat, Bojan Zarić, Igor Gómez-Randulfe Rodríguez, Jelena Spasić, Rafal Dziadziuszko	
10:30–10:45	Coffee break	

10:45-12:15	**Lung Cancer Masterclass – part 3** **Oncogene-addicted NSCLC** Moderators: Jelena Spasić, Katja Mohorčić	
10:45–10:55	Intro: Standard of care of EGFR and ALK positive NSCLC	Marko Jakopović
10:55–11:10	New treatment options for advanced EGFR mutated NSCLC	Urška Janžić
11:10–11:25	Advances in other/rare mutations (beyond EGFR and ALK)	Igor Gómez-Randulfe Rodríguez
11:25–11:40	Therapy sequencing and acquired resistance	Sanjay Popat
11:40–11:55	Adjuvant treatment of EGFR and ALK positive NSCLC	Davorin Radosavljević
11:55–12:15	Panel discussion: Davorin Radosavljevic, Sanjay Popat, Marko Jakopović, Urška Janžič, Igor Gómez-Randulfe Rodríguez	
12:15–12:30	Coffee break	
12:30–13:30	**Lung Cancer Masterclass – part 4** **SCLC** Moderators: Bojan Zarić, Urška Janžić	
12:30–12:40	Intro: An area of unmet need or are we doing better in the treatment of SCLC?	Jelena Spasić
12:40–12:55	Radiotherapy in SCLC	Rafal Dziadziuszko
12:55–13:10	Advances in systemic therapy of SCLC	Katja Mohorčić
13:10–13:30	Panel discussion: Jelena Spasić, Rafal Dziadziuszko, Katja Mohorčič, Igor Gómez-Randulfe Rodríguez	
13:30–14:15	**Sponsored symposium 2** **ROCHE** **New scenario** Moderator: Bojan Zarić Futurospection – Bojan Zarić New roles – Bojan Zarić, Natalija Samardžić, Davorin Radosavljević Plot twist: Patient on the scene - Bojan Zarić, Natalija Samardžić, Davorin Radosavljević	
14:15–15:10	Lunch	
15:10–15:40	**Sponsored symposium 3** **ASTRAZENECA** **EGFRevolution - 20Y of EGFm** *Expert perspectives and panel discussion* Moderator: Bojan Zarić Panelists: Milica Kontić Jovanović, Radmila Janković, Nebojša Marić	

15:40-16:25	**Sponsored symposium 4** **PFIZER** Moderator: Bojan Zarić 1L lorlatinib in ALK+ NSCLC: 5 years later - Marko Jakopović Changing the conversation in 1L ALK+ NSCLC: Treatment decision-making – Bojan Zarić Our experience with Lorlatinib – Natalija Samardžić	
16:25–16:30	Break	
16:30–19:00	**ESSO Young Surgeons and Alumni Club (EYSAC) Research Academy Workshop, joined with Serbian Society of Surgical Oncology** Organizers: Nada Santrač (EYSAC Chair), Wim Ceelen (EYSAC Research Academy senior lead)	
16:30–16:45	ESSO & EYSAC: where are we now?	Nada Santrač
16:45–17:00	Disparities in cancer treatment	Johnn Henry Herrera Kok
17:00–17:45	**Workshop part 1** Moderators: Nada Santrač, Nikolaos Vassos	
17:00–17:30	How to start with translational and clinical research?	Wim Ceelen
17:30–17:45	Q&A	
17:45–18:10	Coffee break	
18:10–18:55	**Workshop part 2** Moderators: Wim Ceelen, Milan Kocić	
18:10–18:40	How to best use the RedCap platform for data acquisition and analysis?	Dara Lundon
18:40–18:55	Q&A	
18:55–19:00	**Workshop take-home messages** Wim Ceelen, Nada Santrač	

61st ONCOLOGY CONGRESS

13–16th November 2024

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 3, November 15th 2024, FRIDAY

HALL A

08:00–09:30	**Scientific session 1** **Cutaneous melanoma – modern treatment concept** Moderators: Ivan Marković, Suzana Matković, Nada Santrač	
	Introduction	
08:00–08:10	Modern molecular diagnostics in melanoma	Radmila Janković
08:10–08:30	Optimizing surgery and systemic treatment of non-metastatic cutaneous melanoma	Piotr Rutkowski
08:30–08:40	National Melanoma Guidelines – updates in adjuvant treatment	Borislava Nikolin
08:40–08:50	National Melanoma Guidelines – updates in systemic treatment	Suzana Matković
08:50–09:25	Panel discussion: speakers, Emina Milosavljević, Milica Rajović, Marko Jevrić, Tatjana Radević, Željko Mijušković, Ivan Petković	
09:25–09:30	Conclusions	
09:30–10:15	**Sponsored symposium 1** **MSD** **The key to better outcomes in the treatment of malignant diseases** Speakers: Lazar Popović, Suzana Matković, Marijana Milović Kovačević, Zoran Andrić	
10:15–10:20	Break	
10:20–11:40	**Scientific session 2** **Novelties in the treatment of endometrial carcinoma** Moderator: Marijana Milović Kovačević	
10:20–10:30	Novelties in pathology reporting for endometrial carcinoma	Svetlana Milenković
10:30–10:40	Panel discussion: Irena Jovanić, Radmila Janković	
10:40–10:50	Novelties in surgical treatment of endometrial carcinoma	Petar Radlović

10:50–11:00	Panel discussion: Lazar Nejković, Aljoša Mandić, Katarina Stefanović	
11:00–11:10	Novelties in systemic treatment of endometrial carcinoma	Marijana Milović Kovačević
11:10–11:20	Panel discussion: Andjela Karaferić, Mirjana Miković, Radmila Janković	
11:20–11:30	Novelties in radiotherapy of endometrial carcinoma	Mirjana Miković
11:30–11:40	Panel discussion: Aleksandar Tomašević, Marija Živković Radojević, Ilinka Todorovska, Lidija Pavlović	
11:40–12:10	**Sponsored symposium 2** **AstraZeneca** **Ovarian cancer chronicles: From BRCA foundations to HRD horizons** Speakers: Marijana Milović Kovačević, Radmila Janković	
12:10–13:20	Lunch	
13:00–19:00	**SSSO-ESES-ESSO Thyroid Cancer Masterclass** organized by *Serbian Society of Surgical Oncology*, endorsed by *European Society of Endocrine Surgery* and *European Society of Surgical Oncology* Organizers: Ivan Marković, Nada Santrač, Kyriakos Vamvakidis	
13:00–13:45	**Thyroid Cancer Masterclass – part 1** **Diagnostics and pathology of thyroid cancer** Moderators: Kyriakos Vamvakidis, Miloš Žarković	
13:00–13:15	Evaluation and management of thyroid nodules: integrating imaging, cytology and molecular markers	Pablo Valderrábano
13:15–13:30	Aggressive histological variants of thyroid cancer and implications in clinical practice	Svetislav Tatić
13:30–13:45	Panel discussion: Joaquin Gomez Ramirez, Nikola Slijepčević, speakers	
13:45–14:50	**Thyroid Cancer Masterclass – part 2** **Differentiated thyroid cancer** Moderators: Ioannis Koutelidakis, Ivan Marković	
13:45–14:00	Surgery of differentiated thyroid cancer: when should we be less aggressive?	Joaquin Gomez Ramirez
14:00–14:15	Optimization of the follow-up of differentiated thyroid cancers	Miloš Žarković
14:15–14:30	Genetics and thyroid cancer: from differentiation to dedifferentiation and back	George Simeakis

14:30–14:50	Panel discussion: Kyriakos Vamvakidis, Svetislav Tatić, speakers	
14:50–15:10	Coffee break	
15:10–16:30	**Thyroid Cancer Masterclass – part 3** **Advanced thyroid cancer** Moderators: Kerstin Lorenz, Pablo Valderrábano	
15:10–15:25	Precision medicine in advanced thyroid cancer: clinical utility of genetic testing in the tumor-agnostic era	George Simeakis
15:25–15:40	New trends in surgical treatment of advanced thyroid cancer	Ioannis Koutelidakis
15:40–15:55	Management of infiltrated inferior laryngeal nerve and requirements for decision making	Nada Santrač
15:55–16:10	Thyroid cancer in children and adolescents	Marko Buta
16:10–16:30	Panel discussion: Ozer Makay, Ivan Marković, speakers	
16:30–16:40	Coffee break	
16:40–17:35	**Thyroid Cancer Masterclass – part 4** **Medullary thyroid cancer** Moderators: Joaquin Gomez Ramirez, Marko Buta	
16:40–17:00	New strategy for surgical management and follow-up of sporadic medullary thyroid cancer	Kerstin Lorenz
17:00–17:15	Surgical recommendations for management of hereditary medullary thyroid cancer	Kyriakos Vamvakidis
17:15–17:35	Panel discussion: Ioannis Koutelidakis, Sanja Ognjanović, speakers	
17:35–17:40	Break	
17:40–18:40	**Thyroid Cancer Masterclass – part 5** **Complications in thyroid cancer surgery: prevention and management** Moderators: Ozer Makay, Nada Santrač	
17:40–18:00	Standard and alternative techniques for intraoperative neuromonitoring during thyroid surgery	Ozer Makay
18:00–18:15	Modern technologies for preservation of parathyroid glands during thyroid surgery	Ioannis Koutelidakis
18:15–18:35	Management of complications in thyroid cancer surgery	Ivan Marković
18:35–18:55	Panel discussion: Kerstin Lorenz, Miloš Žarković, speakers	
18:55–19:00	**Masterclass conclusions** Ivan Marković, Nada Santrač, Kyriakos Vamvakidis	

HALL C		
14:00–15:50	**Scientific session 1** **Hereditary cancer syndromes in clinical practice – multidisciplinary approach, standard of care and strategy for the future** Moderators: Ana Krivokuća, Snežana Šušnjar, Davorin Radosavljević	
14:00–14:25	Genetic testing and applying new technologies in the field of hereditary cancers in Slovenia	Srđan Novaković
14:25–15:05	**Part 1 – Hereditary breast cancer**	
14:25–14:35	Genetic testing in hereditary breast cancer – IORS experiences	Ana Krivokuća
14:35–14:45	Prevention of disease onset in healthy mutation carriers and disease course in patients with hereditary breast cancer	Marko Spasić
14:45–14:55	Modern systemic treatment of hereditary breast cancer	Snežana Šušnjar
14:55–15:05	Q&A, discussion	
15:05–15:45	**Part 2: Hereditary nonpolyposis colorectal cancer**	
15:05–15:15	Genetic testing in hereditary nonpolyposis colon cancer – IORS experiences	Marija Đorđić Crnogorac
15:15–15:25	Prevention of disease onset in healthy mutation carriers and disease course in patients with hereditary nonpolyposis colon cancer	Vladimir Jokić
15:25–15:35	Modern systemic treatment of hereditary nonpolyposis colon cancer	Davorin Radosavljević
15:35–15:45	Q&A, discussion	
15:45–15:50	**Conclusions**	
15:50–16:00	Break	
	Oral presentations of selected abstracts (5 minutes each presentation, 10 minutes for discussion)	
16:00–16:55	**Part I: Breast & Gynecology** Moderators: Sanja Lekić, Vladimir Tvrdišić, Ivana Rosić	
16:55–17:00	Break	
17:00–18:05	**Part II: Digestive, Lung & Urology** Moderators: Milan Kocić, Feđa Đorđević	
18:05–18:10	Break	
18:10–19:05	**Part III: Miscellaneous** Moderators: Milica Rajović, Mila Purić	

61st ONCOLOGY CONGRESS

13–16th November 2024

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 4, November 16th 2024, SATURDAY

HALL A

08:00–08:30	**Sponsored symposium 1** **BAYER** **Darolutamide in Prostate Cancer: Bridging Epidemiology and Pivotal trials Evidence** Moderator: Zoran Džamić Understanding Prostate Cancer: Epidemiology, Pathophysiology, and the Role of Darolutamide – Zoran Džamić Examining the Evidence: Key Findings from ARAMIS and ARASENS Trials – Suzana Matković	
08:30–09:00	**Sponsored symposium 2** **MERCK** **Erbitux & Bavencio – journey towards better outcome of oncology treatment** Erbitux in the continuum of mCRC treatment– 20 years of heritage – Marija Ristić Bavencio in the treatment of LA/mUC – long term follow up – Lazar Popović Discussion – all participants	
09:00-09:45	**Scientific session 1** **Multidisciplinary treatment of digestive tract malignancies – part 1: Gastric and gastroesophageal cancer** Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić	
09:00–09:20	Modern systemic treatment of gastric and gastroesophageal cancer	Borislav Belev
09:20–09:35	Role of radiotherapy in treatment of locally advanced gastric and gastroesophageal cancer	Nikola Milošević
09:35–09:45	Panel discussion: Zoran Andrić, Dragan Gunjić, speakers	
09:45–10:30	**Sponsored symposium 3** **AMICUS** **Advancing Cancer Care: The Role of Nivolumab and Ipilimumab** Ten-Year Outcomes of Nivolumab and Ipilimumab Combination Therapy in Melanoma – Suzana Matković Nivolumab in Urothelial Carcinoma: Clinical Outcomes and Future	

	Directions – Lazar PopovićLong-Term Outcomes of Nivolumab and Ipilimumab in Renal Cell Carcinoma: An 8-Year Follow-Up Study – Svetlana Salma Nivolumab in CheckMate 649: A Paradigm Shift in Gastric Cancer Treatment – Marija Ristić	
10:30–10:45	Coffee break	
10:45–11:30	**Scientific session 2** **Multidisciplinary treatment of digestive tract malignancies – part 2: Hepatocellular carcinoma** Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić	
10:45–11:00	Locoregional treatments for hepatocellular carcinoma	Sanja Stojanović
11:00–11:15	Modern treatment algorithm for locally advanced hepatocellular carcinoma	Marija Ristić
11:15–11:30	Panel discussion: Mlađan Protić, Nenad Mijalković, Saša Jungić, speakers	
11:30–12:30	**Sponsored symposium 4** **ROCHE/Inpharm** **Navigating the patient journey in HCC treatment: challenges, achievements, and future perspectives** Welcome and introduction – Ivan Nikolić The importance of surveillance and diagnosis – Nenad Mijalković What do the results from IMBrave150 reveal to us? – Ivan Nikolić What can we learn from the RWD? – Marija Ristić The impact of innovative therapy on improving treatment outcomes at KBC Zagreb – Borislav Belev Discussion – All participants	
12:30–12:45	Coffee break	
12:45–13:30	**Scientific session 3** **Multidisciplinary treatment of digestive tract malignancies – part 3: Cholangiocarcinoma** Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić	
12:45–13:00	NGS in cholangiocarcinoma	Radmila Janković
13:00–13:15	Systemic treatment of locally advanced cholangiocarcinoma	Marina Marković
13:15–13:30	Panel discussion: Borislav Belev, Miljana Džunić, Ivan Nikolić, speakers	
13:30–14:00	**Sponsored symposium 5** **NOVARTIS** **Advancements and Challenges in mCRPC - Comprehensive approaches** Moderator: Suzana Matković Speaker: Miloš Veljković	
14:00–15:00	Lunch	

15:00–16:15	**Scientific session 4** **Scientific projects in Serbia** Moderators: Radmila Janković, Ivana Božović Spasojević	
15:00–15:15	Twinning to skyrocket scientific excellence towards individual radiosensitivity prediction by raising the bar in knowledge transfer, networking, and technological innovation in radiobiology – project: RadExIORSBoost, 101158832	Ivana Matić
15:15–15:30	Functional diagnostics in non-small cell lung carcinoma – a new concept for the improvement of personalized therapy in Serbian patients – project: TargetedResponse, 7739737	Milica Pešić
15:30–15:45	ADCs in oncology: why "magic bullet" does not mean "magic pharmacology	Joseph Ciccolini
15:45–16:15	Discussion	
16:15–18:00	**Scientific session 5** **Translational research in radiobiology** Moderators: Tatjana Stanojković, Marina Nikitović	
16:15–16:28	Biomarkers in radiobiology – challenges and future directions	Nađa Grozdanić Stanisavljević
16:28–16:41	Molecular Markers for Biological Dosimetry in Radiation Protection, Cancer Risk Assessment and Optimizing Radiotherapy	Igor Belyaev
16:41–16:54	RILA test in modern clinical practice	Jelena Stanić
16:54–17:07	The correlation between changes in the levels of IL-6 and TGF-B1 in serum and the occurrence of radiation toxicity in patients with prostate cancer	Katarina Kopčalić
17:07–17:20	Clinical Trials in Slovakia	Daniela Svetlovska
17:20–17:33	Different roles of SOX genes in promotion of malignant behavior of glioblastoma cells	Danijela Drakulić
17:33–17:46	MicroRNA – towards management of glioblastoma	Danijela Stanisavljević Ninković
17:46–18:00	Discussion	
18:00–18:30	**CLOSING REMARKS & evaluation**	

ORAL PRESENTATIONS OF SELECTED ABSTRACTS

Part I – Breast & Gynecology
November 15th 2024, Hall C
16:00–16:55
Moderators: Sanja Lekić, Vladimir Tvrdišić, Ivana Rosić

1. Predrag Jovanovic, Milos Pekovic
   The role of digital breast tomosynthesis in additional diagnostics following screening mammography – Initial experiences from Obrenovac Health Center

2. Nataša Prvulović Bunović, Milica Mastilović, Maja Stankov, Milena Spirovski
   Male breast imaging – Single Institution Experience

3. Aleksandar Martinovic, Nada Santrac, Branka Radmanovic, Jovana Koncar, Nevena Savkovic, Veljko Grabovcic
   Continuation of the trend of increasing numbers in genetic tested patients the Institute for Oncology and Radiology of Serbia

4. Saša Mihajlović, M. Čalamać, O. Djurmez, M. Dimitrijević, K. Šerović, J. Oblaković, N. Stanić, I. Minić, I. Božovic-Spasojević
   Initial experiences with abemaciclib, a selective cyclin-dependent kinase 4/6 inhibitor, in the treatment of early hormone-receptor-positive breast cancer at the Daily Chemotherapy hospital at Institute for Oncology and Radiology of Serbia

5. Marija Dimitrijević, Marina Čalamać, Ognjen Đurmez, Kristina Šerović, Jelena Oblaković, Saša Mihajlović, Ivana Minić, Nemanja Stanić, Ivana Božović-Spasojević
   Efficacy of the CDK4/6 inhibitors plus endocrine therapy (ET) based on hormon receptor expression and endocrine resistance in metastatic breast cancer patients (mBC pts)

6. Ćosović Vojislav, Novaković Teodora, Bobić Simonida, Kutić Slobodan, Mijucić Jovana, Pavlović Lidija, Karaferić Anđela, Matović Milana, Milović-Kovačević Marijana
   Predicting factors for progression free survival (PFS) in breast cancer patients treated with Ribociclib with endocrine therapy (ET)

7. Novakovic Teodora, Bobic Simonida, Kutic Slobodan, Mijucic Jovana, Cosovic Vojislav, Milovic-Kovacevic Marijana
   Efficacy of trastuzumab emtansine (TDM1) in metastatic breast cancer depending on the duration of response to adjuvant HER2 therapy

8. Kristina Janković, Ana Cvetanović, Lazar Stošić, Milan Čevrljaković, Ana Stojković, Marija Jevtić, Ivan Petković
   Male breast cancer: the experience of the oncology clinic university clinical center Niš

9. Kutić S, Karaferić A, Pavlović L, Matović M, Bobić S, Novaković T, Ćosović V, Mijucić J, Milović-Kovačević M
Granulosa cell tumour: 14 years' experience of a Tertiary Center in Serbia

Part II: Digestive, Lung & Urology
November 15th 2024, Hall C
17:00–18:05
Moderators: Milan Kocić, Feđa Đorđević

1. Dejan Stojakov, Radmila Ilić, Radoje Kosanović, Rastko Živić, Miljan Milanović, Zagor Zagorac, Tomislav Palibrk, Miloš Kostić, Anđelija Kostić, Pavle Tasić, Ljubica Tomašević, Marko Đurić, Snežana Zatežić, Predrag Stevanović, Vladimir Đukić
Pharyngolaryngoesophagectomy and pharyngolaryngectomy in radical treatment of advanced T3/T4a squamos cell hypopharyngeal carcinoma

2. Keramatollah Ebrahimi, Predrag Sabljak, Dejan Stojakov, Aleksandar Simić, Ognjan Skrobić, Dejan Veličković, Vladimir Šljukić, Nenad Ivanović, Milan Veselinović, Predrag Peško
Multidisciplinary treatment of GIST of the esophagus and esophagogastric junction

3. Marija Jevtić, Miljana Džunić, Mladen Đorđević, Kristina Janković, Jelena Krstić, Maja Milivojević, Dane Krtinić, Ana Cvetanović
Hepatocellular carcinoma at UKC NIŠ – incidence, patient characteristics, and therapeutic modalities applied

4. Miljana Džunić, Jelena Krstić, Marija Jevtić, Milan Čevrljaković, Ana Cvetanović
The prevalence of KRAS G12C mutation in patients with metastatic colorectal cancer in Southern and Eastern Serbia

5. Bojana Kožik, Lidija Todorović, Ana Božović, Ana Kolaković, Naris Pojskić, Lejla Kapur Pojskić, Tijana Vasiljević, Mladen Đurić, Aleksandar Đermanović, Vesna Mandušić
CDH1 expression as a predictor of metastasis in rectal cancer

6. Filip Marković, Mihailo Stjepanović, Natalija Samardžić, Milica Kontić
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in previously treated advanced non-small cell lung cancer patients: Single center experience

7. Katarina Ljujić, Feđa Đorđević, Dimitrije Kolović, Andrijana Kojić, Nemanja Stanić, Neda Nikolić, Davorin Radosavljević, Jelena Spasić
Pembrolizumab monotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC) – experience from The Institute for Oncology and Radiology of Serbia

8. Kristina Juškić, Sara Ješić, Milica Đurkić, Suzana Matković
   Clear Cell Renal Cell Carcinoma – Application of Nivolumab After First-Line Treatment with a Tyrosine Kinase Inhibitor

9. Milica Đurkić, Sara Ješić, Kristina Juškić, Suzana Matković
   Non-clear cell renal cell carcinoma - use of sunitinib as a first line option for metastatic disease

10. Milan Čevrljaković, Vesna Stojanović, Aleksandra Dimitrijević, Mirjana Todorović Mitić, Dane Krtinić, Kristina Janković, Ivan Petković, Ana Cvetanović
    The use of the anti-PDL1 inhibitor, Avelumab, in patients with advanced and metastatic urothelial carcinoma - the experience of the oncology clinic University clinical center Niš

11. Vještica Milka
    Does waiting for tyrosine kinase inhibitor therapy affect progression-free period and overall survival in patients with renal cell carcinoma?

Part III: Miscellaneous
November 15th 2024, Hall C
18:10–19:05
Moderators: Milica Rajović, Mila Purić

1. Tatjana Radević, Tanja Tirnanić, Branko Dujović, Željko Mijušković, Milica Rajović, Miroslav Dinić, Zoran Bukumirić, Lidija Kandolf
   Correlation of clinicopathological characteristics of the primary tumor, risk factors and disease outcome with BRAF mutations in metastatic melanoma patients-single center analysis

2. Aleksandar Popović, Branko Dujović, Ivana Jocić, Ana Stojković, Marina Petronijević, Nemanja Kolović, Ivan Petković, Mirjana Balić, Suzana Matković, Borislava Nikolin, Tanja Radević, Željko Miljušković, Jovica Glišić, Emina Milosavljević, Lidija Kandolf
   First-line anti PD-1 versus combined targeted therapy in patients with BRAF-mutant advanced melanoma: results from tertiary centers in Serbia

3. Dimitrije Đurđević, Marija Milosavljević, Dušica Gavrilović, Tamara Ursulović
   Use of Pembrolizumab in the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) – a single center experience

4. Marija Živković Radojević, Aljoša Mandić, Katarina Janković, Miloš Grujić, Katarina Krasić, Vladimir Grbić, Nevena Folić, Marko Folić, Ksenija Bošnjaković, Aleksandra Marković, Dragan Lončar, Neda Milosavljević
   International analysis of the level of knowledge about Human papillomavirus infections in the population of young athletes in a volleyball camp

5. Sofija Pantelic, Mila Puric, Aleksandra Drinic, Tatjana Arsenijevic
   Radiological evaluation of "bulky" disease in the mediastinum in a patient with Hodgkin's lymphoma: X-ray vs. MSCT vs. PET/CT

6. Ana Stojković, Aleksandar Popović, Ivan Petković, Ana Cvetanović, Kristina Janković, Lazar Stošić
   Assessment of the neutrophil-lymphocyte ratio in patients with Hodgkin lymphoma (HL): the experience of the Oncology clinic University clinical center Niš

7. Ivana Šović, Mina Vasović Marković, Natalija Zoranović
   Our Experience in Detecting Metastatic Melanoma in the Adrenal Glands: Prognostic and Therapeutic Significance of Abdominal MDCT

8. Mina Vasović Marković, Ivana Šović, Natalija Zoranović
   Metastases of renal carcinoma in the adrenal gland

9. Maja Šapić, Katarina Kovačević, Sanja Manojlov, Aleksandar Stojanović, Aleksandra Erić Nikolić, Mirjan Nadrljanski
   Metastases of primary invasive breast cancer in the adrenal gland – series of patients from the Institute of Oncology and Radiology of Serbia (IORS), in the interval from January to September 2024

POSTER PRESENTATIONS

1. Ana Cvetanović, Nikola Živković, Maja Jovičić Milentijević, Miloš Kostić, Tijana Denčić
   Granular cell tumor dojk-prikaz slučaja
2. Aleksandar Stojanović, Mina Vasović, Aleksandra Erić Nikolić, Mirjan Nadrljanski
   Typical and atypical (endocrine) metastatic sites of renal cell carcinoma (RCC) – case report
3. Aleksandar Radulović, Zoran Tomašević
   Primena imunoterapije kod HER2+ AR+ karcinoma parotidne žlezde – prikaz slučaja
4. Aleksandar Šipka, Marina Đurić, Miroslav Tomić, Aljoša Mandić
   Komplikacije operativnog lečenja recidiva Pedžetove bolesti vulve: lečenje i praćenje
5. Koljević Marković Ana
   Evaluation of the protocol duration in the lymphoscintigraphy detection of sentinel melanoma metastases
6. Ana Stojković, Aleksandar Popović, Ivan Petković, Ana Cvetanović, Ana Petrović, Kristina Janković
   Kompletan odgovor na terapiju polatuzumab-vedotin+rituximab+bendamustin u relaps/refraktarnom difuznom b krupnoćelijskom limfomu želuca (R/R PG-DBKL) – prikaz slučaja
7. Ana Petrović, Aleksandar Popović, Ivan Petković, Ana Stojković, Mirjana Balić, Ana Cvetanović
   Pembrolizumab as a bridge to autologous stem cell transpalantation (ASCT) in patients with refractory hodgkin
8. Ana Stojković, Aleksandar Popović, Ivan Petković, Mirjana Balić, Ana Cvetanović
   Pembrolizumab-induced type I diabetes mellitus in a patient with metastatic melanoma – case report
9. Ana Stojković, Ivan Petković, Aleksandar Popović, Kristina Janković, Miljana Džunić, Jelena Krstić, Ana Cvetanović
   Serious dermatological toxicity associated with the use of imatinib mesylate ih the treatment of metastatic gastrointestinal stromal tumor (GIST) of the ileum – case report
10. Andjela Dimkić Milenković, Milan Jovanović
    Basal Cell Carcinoma of the head with unproper margins
11. Andrijana Kojić, Feđa Đorđević, Katarina Ljujić, Dimitrije Kolović, Jelena Spasić
    Toxicity of brigatinib in the treatment of metastatic ALK-positive non-small cell lung
12. Anđelija Cvetković, Sanja Mitrović, Dejan Stojiljković, Zoran Kozomara, Dobrica Stević, Milan Žegarac
    Malignant Mesenchymal Tumor of the Peripheral Nerve Sheath Two Decades After Melanoma – Case Report

13. Borislava Nikolin, Nemanja Kolović; Marko Marjanović
Long-term and favorable outcome of metastatic melanoma treatment

14. Borislava Nikolin, Nemanja Kolović; Marko Marjanović
L-term response and favorable outcome of treatment of metastatic squamous cell carcinoma of the head and neck by sequencing therapy

15. Branko Dujović, Aleksandar Popović, Lidija Kandolf, Igor Salatić, Ivana Jocić, Bojana Cikota Aleksić
Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-pdi monotherapy: a multicentric analysis

16. Danijela Niciforovic, Katarina Milojevic, Marina Markovic, Dragica Pavlovic, Dragana Papic
Immune-related Adverse Events – The importance of early diagnosis and treatment of Pembrolizumab induced microscopic colitis: A Case Report

17. Dimitrije Đurđević, Sofija Pantelić, Marija Milosavljević, Mila Purić, Tamara Ursulović
Nivolumab induced thrombocytopenia in patient with metastatic melanoma – a case report

18. Dimitrije Đurđević, Valentina Karadžić, Dejan Stoiljković, Marija Milosavljević, Radmila Janković, Tamara Ursulović
Detection of a BRAF V600E mutation from circulating tumor DNA isolated from the pleural punctate in the patient with metastatic melanoma – a case report

19. Branko Dujović, Lidija Kandolf, Igor Salatić, Bojana Cikota Aleksić
Korelacija inicijalne koncentracije slobodno cirkulišuće dnk sa kliničko-patološkim karakteristikama kod pacijenata sa uznapredovalim melanomom

20. Dimitrije Đurđević, Marija Milosavljević, Dušica Gavrilović, Tamara Ursulović
Use of Pembrolizumab in the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) – a single center experience

21. Dragana Petrović Popović, Marijan Novaković, Mirjana Petrović Elbaz
Naš prvi pacijent sa melanocitnim tumorom neodređenog malignog potencijala

22. Dimitrije Kolović, Katarina Ljujić, Andrijana Kojić, Feđa Đorđević, Neda Nikolić, Marija Ristić, Davorin Radosavljević, Vladimir Nikolić, Jelena Spasić
The use of durvalumab as maintenance therapy after chemoradiotherapy (CRT) in unresectable non-small cell lung cancer (NSCLC) clinical stage III (CS III) – the experience of the Institute of Oncology and Radiology of Serbia (IORS)

23. Dobrica Stević, Emilija Filipović, Anđelija Cvetković, Ognjen Đurmez, Nataša Medić Milijić, Milan Žegarac
Melanoma in a patient on fingolimod (Gilenya) therapy for multiple sclerosis – case report

24. Emilija Filipovic, Ana Lazarevic, Lila Rajacic
Breast tumor with myofibroblastic differentiation in a young patient – case report

25. Irena Conić, Slavica Stojnev, Ivan Petković, Ana Cvetanović, Dane Krtinić, Milica Radić, Marijana Milović Kovačević
Low-grade serous adenocarcinoma of the ovary with metastases in cervical and axillary lymph nodes

26. Ivana Bozović Spasojević, Marijana Milović Kovacević, Ana Cvetanović, Ivana Kolarov Bjelobrk, Jelena Lucić, Zoran Andrić, Dušan Milenković, Marina Petronijević, Marina Čalamać, Ognjen Đurmez, Stefan Đurić, Vladimir Perduv, Lazar Popović
Real world treatment patterns in patients with human epidermal growth factor receptor 2 (HER2) - positive early breast cancer in Serbia - HEReNA

27. Filipović Jelena, Jevrić Marko, Salatić Igor, Brašanac Dimitrije, Griewank Klaus, Hauschild Axel, Schadendorf Dirk, Stojanović Milosavljević Miona, Denčić-Fekete Marija, Sondak Vernon, Žegarac Milan, Kandolf Lidija
Neonatal Melanoma with Lymph Node Metastasis

28. Ivana Mitić, Irena Conić, Ana Cvetanović, Ilinka Todorovska, Ivan Petković
Case report of a patient with duplex carcinoma of the breast and ovary

29. Jelena Perović, Teodora Urošević, Stela Novak, Aleksandar Đurić
Diagnostic challenges in patients with five metachronous primary tumors

30. Jelena Krstić, Miljana Džunić, Milan Čevrljaković, Marija Jevtić, Dušan Radomirović, Ana Stojković, Ivan Petković, Ana Cvetanović
Durvalumab in combination with gemcitabine and cisplatin in the treatment of metastatic cholangiocellular carcinoma: a case report

31. Jovana Trifunović, Nemanja Trifunović, Sara Filipović, Miroslav Kreačić
Pseudomyxoma peritonei: A progression-free interval (PFI) of 20 months on the third line ofsystemic metronomic chemotherapy

32. Jovana Mitrovski, Jelena Pavlović, Mirjana Todorović Mitić, Maja Milivojević, Ana Cvetanović, Ivan Petković
Prikaz pacijenta sa kožnim melanomom u trećem kliničkom stadijumu lečenog adjuvantnom terapijom Pembrolizumabom- trogodišnje

33. Katarina Janković, Slađana Aćimović Talijan, Marija Živković Radojević
Radioterapija hepatocelularnog karcinoma jetre : Prikaz slučaja

34. Katarina Milojević, Aleksandar Dagović, Danijela Nićiforović, Dalibor Jovanović, Vesna Stanković, Marina Marković
Retroperitonealni maligni perivaskularni epiteloidni tumor- prikaz slučaja

35. Katarina Milojević, Aleksandar Dagović, Danijela Nićiforović, Dalibor Jovanović, Dragica Pavlović, Dragana Papić, Marina Marković
Značaj upotrebe checkpoint inhibitora u terapiji NSCLC kod pacijenta sa T-ćelijskim limfomom – prikaz slučaja

36. Kristina Janković, Ana Cvetanović, Milan Čevrljaković, Ana Stojković, Ivan Petković, Irena Conić
Immunotherapy in the treatment of early triple negative breast cancer: a case report

37. Maja Stankov, Milica Mastilović, Ivan Ađić, Nataša Prvulović Bunović
Embrionalni rabdomiosarkom mokraćne bešike – prikaz slučaja

38. Maja Milivojević, Miljana Džunić, Marija Jevtić, Jelena Pavlović, Jovana Mitrovski, Dragana Ševo, Ivan Petković, Ana Cvetanović
Cutaneous metastases of rectal carcinoma : case report

39. Maja Stankov, Milica Mastilović, Ivana Stojić, Nataša Prvulović Bunović
Imidžing karakteristike solidnih lezija bubrega

40. Marija Živković Radojević, Aleksandra Marković, Neda Milosavljević, Miloš Grujić, Olivera Milošević-Đorđević
Analiza faktora na hromozomsku nestabilnost u perifernim limfocitima kod pacijentkinja sa karcinomom endometrijuma

41. Marija Urošević, Zoran Tomašević
Pneumonitis kao neželjeni efekat primene imunološke terapije: prikaz slučaja

42. Marina Petronijević, Nevena Ranđelović, Jelena Lučić, Marija Spasojević
Rare metastasis of lobular breast carcinoma to the appendix – case report

43. Marina Petronijević, Nevena Ranđelović, Jelena Lučić, Marija Spasojević
Late metastases of carcinoma of the rectosigmoid colon in the endocranium – case report

44. Marina Petronijević, Nevena Ranđelović
Differential diagnostic dilemma between STUMP and uterine leiomyosarcoma – case report

45. Milan Čevrljaković, Vesna Stojanović, Aleksandra Dimitrijević, Kristina Janković, Ivan Petković, Ana Cvetanović
Long-term response after using of avelumab in patient with urothelial carcinoma:a case report

46. Marko Marjanović, Borislava L. Nikolin, Nemanja Kolović
Favorable outcome of treatment with mono immunotherapy of metastatic squamous cell carcinoma of the larynx

47. Milan Risteski, Biljana Ognenovska
Case report of aromatase inhibitors induced arthralgia

48. Marko Marjanović, Borislava Nikolin, Nemanja Kolović
Treatment options for BRAF wild type metastatic melanoma

49. Maša Jovićević, Biljana Kukić, Zoran Radovanović
Genetic predisposition and family risk: The role of familial adenomatous polyposis in the development of colon cancer

50. Mastilović Milica, Stankov Maja, Borislava Nikolin, Prvulović-Bunović Nataša
Primary Undifferentiated Pleomorphic Sarcoma of the male breast: a case report

51. Mladen Marinković, Suzana Stojanović-Rundić, Aleksandra Stanojević, Aleksandar Tomašević, Radmila Janković, Nataša Maksimović, Milena Čavić
Multimodal treatment approach for locally advanced rectal cancer – case report

52. Mirjana Jasiković, Snežana Furtula, Snežana Radović, Jelena Dimitrijević
Lečenje anemije kod pacijenta sa karcinomom pluća sukrozomalnim gvožđem-prikaz slučaja

53. Nemanja Kolović, Borislava Nikolin, Marko Marjanović
Sequencing therapy in metastatic squamous cell carcinoma of the head and neck region

54. Nemanja Kolović, Borislava Nikolin, Marko Marjanović
Long-term response to available therapeutic options in the treatment of metastatic melanoma and treatment complications

55. Nevena Ranđelović, Marina Petronijević
Survival of metastatic non-small cell cancer patients with brain metastasis: a single center real-world experience study

56. Nevena Ranđelović, Marina Petronijević, Marija Peulić
Pulmonary sarcomatoid carcinoma – implications of a rare malignancy: Case report

57. Rawnaq Mihajlović, Marina Petronijevic, Teodora Ranković
Retka metastaza karcinoma dojke

58. Rawnaq Mihajlović, Marina Petronijevic, Teodora Ranković
Diferencijalno dijagnostička dilema između virusnog oboljenja, metastaske bolesti i arteficijalnog oštećenja jetre u toku lečenja karcinoma dojke

59. Saška Pavlović, Merima Goran, Nada Santrač, Nikola Jeftić, Nevena Savković, Jovan Raketić, Marko Buta
Radiation induced breast angiosarcoma – case presentation

60. Sara Filipović, Vladimir Samardžić, Ivana Blažić, Jovana Trifunović, Miroslav Kreačić
Metastatic Nonsmall-Cell Lung Cancer Presenting as Primary Adrenal Insufficiency: Case Report

61. Kutić S, Đurđević, Ristić D, Pantelić S, Živković B
Lactate dehydrogenase (LDH) as a predictor of response to neoadjuvant treatment with MAP chemotherapy protocol in osteosarcoma

62. Sofija Pantelic, Branka Zivkovic, Dimitrije Djurdjevic, Slobodan Kutic, Dusan Ristic
Ewings sarcoma – a case report, metastases in the maxillary and sphenoidal sinus?

63. Teodora Urošević, Jelena Perović, Stela Novak, Đorđe Belić
Bowel obstruction caused by breast cancer metastasis

64. Stela Novak, Jelena Perović, Teodora Urošević, Đorđe Belić
Therapeutic effect of the use of CDK4/6 and aromatase inhibitors in patients treated for breast cancer with bone metastases

65. Petrović Ognjen, Nikolić Srđan, Kocić Milan, Jokić Vladimir, Pejnović Luka, Vučić Nikola, Đurišić Igor
Primary leiomyosarcoma of the inferior vena cava-radical resection and vascular reconstruction:case report

66. Valentina Karadžić, Marija Đorđić Crnogorac, Ana Krivokuća
The spectrum of Lynch syndrome-associated germline mutations – First report in Serbia

67. Vanja Stevanović, Ana Damjanović, Aleksandra Stanojević, Valentina Karadžić, Miodrag Vuković, Jelena Kijac, Vesna Ćeriman Krstić, Milena Čavić, Radmila Janković
Highlighting the significance of T790M EGFR mutation testing through repeated liquid biopsy over time

68. Zoran Gajić, Lela Milovanovic, Bozica Radovanovic, Suzana Dimitrijevic, Vesna Stevic Gajic, Blagoje Milovanovic, Jelena Cvetkovic, Milos Milenkovic, Dusan Milojkovic, Radomir Milovanovic
Time from sample collection to the aplication of the first specific parenteral therapy at the day hospital for chemotherapy in Krusevac in 2024

37. SIMPOZIJUM MEDICINSKIH SESTARA-TENHIČARA ONKOLOŠKIH INSTITUCIJA REPUBLIKE SRBIJE

15–16. novembar 2024. • „Sava centar“ • Beograd, Srbija

Dragan Kodžo,
Predsednik Sekcije sestara u onkologiji UMSTBS

Slađana Sokolović
Sekretar Sekcije sestara u onkologiji UMSTBS

Stručni odbor

Mirjana Gavrilović, dipl. def., vms, predsednik
Jasmina Paunković, vms
Suzana Momčilović-Stojković, vms
Dragan Kodžo, mss, specijalista kl. nege
Vera Mandić, vms
Dragana Mušikić Kraker, vms
Danica Pavlović, vms
Slađana Sokolović, vms
Snežana Čurić, vms
Zorica Marinković,vms
Nataša Bakić, vms
Jelica Perović, vlt
Tanja Šljivić-Bojić, vms
Vesna Radojičić, vms
Jasmina Subotić, vms
Sandra Spajić, vms

Organizacioni odbor

Slađana Sokolović, vms,
predsednik
Jelisaveta Vidosavljević, vss
Milica Damjanov, ms
Sanela Mitrović vss

37. SIMPOZIJUM MEDICINSKIH SESTARA-TENHIČARA ONKOLOŠKIH INSTITUCIJA REPUBLIKE SRBIJE

„Novi izazovi su naša budućnost“

NAUČNI PROGRAM

1. dan, petak, 15. novembar 2024.		
08:30–14:00	**Registracija učesnika**	
09:30–10:00	**Svečano otvaranje 37. Simpozijuma**	
10:00–10:10	**Modaliteti lečenja Hočkinovog limfoma – sestrinski aspekti** (uvodna reč moderatora)	**Moderator: Sanela Mitrović,** Strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije
10:10–10:25	**Hemioterapijski pristup u lečenju obolelih od Hočkinovog limfoma** (predavanje)	**Kristina Stošić,** Master strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije
10:25–10:40	**Primena ciljane terapije u lečenju obolelih od Hočkinovog limfoma – Brentuximab vedotin** (predavanje)	**Milena Lovas,** Strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije
10:40–10:55	**Radioterapijski pristup u lečenju Hočkinovog limfoma** (predavanje)	**Jelena Cigulajkić,** Viši radiološki tehničar, Institut za onkologiju i radiologiju Srbije
10:55–11:10	**Značaj medicinske sestre kod transplantacija matičnih ćelija hematopoeze u lečenju obolelih od Hočkinovog limfoma** (predavanje)	**Slobodanka Zelić,** Viša medicinska sestra – tehničar, Klinika za hematologiju, Univerzitetski Klinički centar Srbije
11:10–11:20	Diskusija	
11:20–11:30	Kafe pauza	
11:30–11:40	**Hitna stanja u onkologiji** (uvodna reč moderatora)	**Moderator: Jelena Stepanović** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije

11:40–11:55	**Sindrom tumorske lize** (predavanje)	**Tamara Ursulović,** prim. dr sc. med., Institut za onkologiju i radiologiju Srbije
11:55–12:10	**Kompresija kičmene moždine – multidisciplinarni pristup u lečenju i zdravstvenoj nezi** (predavanje)	**Snežana Sekulić,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
12:10–12:25	**Pozicioniranje, imobilizacija i verifikacija plana u radioterapiji kod sindroma vene kave superior** (predavanje)	**Kristina Jovanović,** Viši radiološki tehničar, Klinika za onkologiju, Univerzitetski Klinički centar Niš
12:25–12:40	**Zbrinjavanje hitnih stanja kod obolelih od akutnih leukemija** (predavanje)	**Živanka Marinković,** Strukovna medicinska sestra, Klinika za hematologiju, Univerzitetski Klinički centar Srbije
12:40–12:55	**Sestrinske intervencije kod febrilne neutropenije** (predavanje)	**Bojana Urošev,** Strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije
12:55–13:10	**Specifičnosti u tretmanu pacijenata sa sepsom u jedinici hirurškog intenzivnog lečenja** (predavanje)	**Jelena Rašeta,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
13:10–13:20	Diskusija	
13:20–14:20	Pauza za ručak	
14:20–14:50	**Sponzorisani Simpozijum Kompanija – Eli Lilly** Uz dobru adherencu do boljih ishoda lečenja u ranom HR+ HER2- karcinomu dojke	**dr Lidija Pavlović, Gorica Marinković,** Strukovna medicinska sestra
14:50–15:00	**Iskustva u kliničkoj praksi medicinskih sestara – tehničara u onkologiji** (uvodna reč moderatora)	**Moderator: Jelena Jakovljević,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
15:00–15:07	**Edem mozga kod pacijenata sa moždanim metastazama na radioterapijskom tretmanu** (usmena prezentacija)	**Vida Živković,** Medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
15:07–15:14	**Krvarenje kao urgentno stanje u brahiterapiji uznapredovalog karcinoma grlića materice** (usmena prezentacija)	**Nebojša Ignjatović,** Klinika za onkologiju, Univerzitetski Klinički centar Niš

15:14–15:21	**Dermatološka toksičnist kod primene radioterapije i Cetuksimaba, kod pacijenata sa malignim tumorima glave i vrata – sestrinski aspekti** (usmena prezentacija)	**Jagoda Radovanović,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
15:21–15:28	**Metroragija kod pacijentkinja sa karcinomom grlića materice – sestrinski aspekti** (usmena prezentacija)	**Jasna Petrov,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
15:28–15:35	**Savremeni pristup u lečenju pacijentkinja sa HER2 pozitivnim karcinomom dojke – sestrinski aspekti** (usmena prezentacija)	**Silvana Milovanović,** Medicinka sestra – tehničar, Institut za onkologiju i radiologiju Srbije
15:35–15:42	**Medicinske sestre u ranoj detekciji i podršci pacijentkinjama sa karcinomom jajnika** (usmena prezentacija)	**Tijana Palković, Emilija Kurtić, Milena Maricic** Akademija strukovnih studija Beograd, Odsek Visoka zdravstvena škola, Srbija
15:42–15:49	**Doprinos medicinske sestre u postoperativnoj nezi pacijentkinja nakon hirurškog lečenja karcinoma dojke** (usmena prezentacija)	**Emilija Nastić, Mira Kovačević, Vanja Pažun** Akademija strukovnih studija Beograd, Odsek Visoka zdravstvena škola, Srbija
15:49–16:00	Kafe pauza	
16:00–16:07	**Zdravstveno vaspitni rad sa pacijentima posle hirurškog zahvata na plućima** (usmena prezentacija)	**Maja Vučković,** Strukovna medicinska sestra, Klinika za grudna hirurgiju Univerzitetski Klinički centar Srbije
16:07–16:14	**Specifičnosti zbrinjavanja i nege pacijenata u toku primene MATRIX režima** (usmena prezentacija)	**Tatjana Petković,** Strukovna medicinska sestra Klinika za onkologiju, Univerzitetski Klinički centar Niš
16:14–16:21	**Izazovi za medicinske sestre – tehničare kod modaliteta lečenja Hočkinovog limfoma** (usmena prezentacija)	**Nenad Brkić,** Strukovni medicinski tehničar – specijalista, Klinika za hematologiju, Univerzitetski Klinički centar Srbije
16:21–16:28	**Problem savremene medicine – Aktivna participacija pacijenata u prevenciji bolničkih infekcija** (usmena prezentacija)	**Melita Memiši** Master strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije

16:28–16:35	**Nega pacijenata nakon maksilektomije – Prikaz slučaja** (usmena prezentacija)	**Ivana Jandrić,** Viša medicinska sestra, Klinika za ORL i MFH, Univerzitetski Klinički centar Srbije
16:35–16:42	**Zdravstvena nega pacijenata operisanih ELAPE metodom** (usmena prezentacija)	**Jelena Berenić,** Strukovna medicinska sestra, Institut za onkologiju Vojvodine
16:42–16:52	Diskusija	
2. dan, subota, 16. novembar 2024.		
08:45–11:00	**Registracija učesnika**	
09:00–09:10	**Suportivna onkologija – multidisciplinarni pristup** (uvodna reč moderatora)	**Moderator: Nataša Bakić,** Viša medicinka sestra – tehničar, Institut za onkologiju i radiologiju Srbije
09:10–09:25	**Suportivna onkologija – izazov za multidisciplinarni tim** (predavanje)	**Nataša Bakić,** Viša medicinka sestra – tehničar, Institut za onkologiju i radiologiju Srbije
09:25–09:40	**Dermatološka toksičnost antineoplastičnih lekova** (predavanje)	**Snežana Bošnjak,** prof. dr sc. med., N.Sav, Institut za onkologiju i radiologiju Srbije
09:40–09:55	**Kožna toksičnost kao neželjeno dejstvo imunološke terapije – prikaz slučaja** (predavanje)	**Vesna Mitrović,** Viša medicinka sestra – tehničar, Institut za onkologiju i radiologiju Srbije
09:55–10:10	**Primena faktora rasta u prevenciji i terapiji febrilne neutropenije kod onkoloških pacijenata koji se leče hemioterapijom** (predavanje)	**Jelena Dimitrijević,** kl. ass, specijalista interne medicine, Institut za onkologiju i radiologiju Srbije
10:10–10:25	**Primena faktora rasta – iskustva iz IORS** (predavanje)	**Nataša Lazin,** Medicinka sestra – tehničar, Institut za onkologiju i radiologiju Srbije
10:25–10:40	**Psihološka podrška mladih u toku onkološkog lečenja** (predavanje)	**Marija Andrijić,** dr sc. med., psiholog, Institut za onkologiju i radiologiju Srbije
10:40–10:50	Diskusija	

10:50–11:00	Kafe pauza	
11:00–11:10	**Iskustva u kliničkoj praksi medicinskih sestara – tehničara u onkologiji** (uvodna reč moderatora)	**Moderator: Bojana Velisavljević,** Strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije
11:10–11:17	**Suočavanje s malignom bolesti** (usmena prezentacija)	**Ivona Poljak,** mag. psych, Klinika za onkologiju, Kliničko-bolnički centar Zagreb, Hrvatska
11:17–11:24	**Indikacije za transplantaciju matičnih ćelija hematopoeze** (usmena prezentacija)	**Branislava Eremija,** Viša medicinka sestra – tehničar, Odeljenje za transplantaciju koštane srži sa laboratorijom za kriobiologiju, Institut za zdravstvenu zaštitu majke i deteta Srbije „Dr Vukan Čupić“
11:24–11:31	**Uloga medicinske sestre u lečenju onkoloških pacijenata** (usmena prezentacija)	**Milica Damjanov,** Medicinska sestra, Institut za onkologiju i radiologiju Srbije
11:31–11:38	**ENDO-EHO korak bliže do terapije** (usmena prezentacija)	**Lazar Mihajlović,** Medicinski tehničar, KBC Dragiša Mišović
11:38–11:45	**Kognitivni poremećaj i delirijum postoperativnih pacijenata Uloga medicinske sestre – tehničara u primeni Dexmedetomidina** (usmena prezentacija)	**Nataša Musulin,** Strukovna medicinska sestra Institut za onkologiju Vojvodine
11:45–11:52	**Uloga medicinske setre kod sprovođenja (CORE) biopsije** (usmena prezentacija)	**Anđelina Sević,** Medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
11:52–11:59	**Centralna priprema citostatika u Institutu za onkologiju KCCG – naša iskustva** (usmena prezentacija)	**Marina Mijović,** Institut za onkologiju Klinički Centar Crne Gore
11:59–12:06	**Sestrinske aktivnosti u lečenju pacijentkinja sa metastatskim karcinomom dojke** (usmena prezentacija)	**Danka Stanković,** Medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije

12:06–12:13	**SBRT (stereotactic body radiation therapy) uz pomoć respiratornog gejtinga** (usmena prezentacija)	**Slađana Tomić,** Specijalista strukovni medicinski radiolog, Institut za onkologiju Vojvodine
12:13–12:20	**Jednodnevna hirurgija kao primer dobre prakse Benefiti jednodnevne hirurgije za pacijente uz sveobuhvatno angažovanje medicinskog osoblja** (usmena prezentacija)	**Dragana Cvetković,** Strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije
12:20–12:27	**Tretman pacijentkinja kod intersticijalne brahiterapije dojke** (usmena prezentacija)	**Marija Basta,** Strukovni medicinski radiolog, Institut za onkologiju Vojvodine
12:27–12:34	**Neželjeni efekti zračne terapije kod maksilofacijalnih pacijenata** (usmena prezentacija)	**Marina Vučić,** Medicinska sestra-tehničar, Klinika za onkologiju, Univerzitetski Klinički centar Niš
12:34–12:41	**Perkutana biopsija koštane srži** (poster prezentacija sa video snimkom)	**Ana Milovanović,** Medicinska sestra – tehničar, Klinika za onkologiju, Univerzitetski Klinički centar Niš
12:41–12:49	**Zbrinjavanje nuspojava peroralne onkološke terapije u Poliklinici** (poster prezentacija)	**Farah Al-Khazae, Josipa Viljevac, Blaženka Pavlović, Vesna Kralj-Škoc, Iva Zubatović Đunđenac** Klinika za onkologiju, KBC Zagreb
12:49–13:00	Diskusija	
13:00–14:00	Pauza za ručak	
14:00–14:10	**Prevencija, lečenje i zdravstvena nega obolelih od melanoma** (uvodna reč moderatora)	**Moderator: Jelena Vagić,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
14:10–14:25	**Prevencija i epidemiologija melanoma** (predavanje)	**Vera Mandić,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
14:25–14:40	**Limfoscintigrafija u dijagnostici melanoma – sestrinski aspekt** (predavanje)	**Branka Džekulić,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije

14:40–14:55	**Hirurško lečenje i zdravstvena nega obolelih od melanoma** (predavanje)	**Jelena Vagić,** Viša medicinska sestra – tehničar, Institut za onkologiju i radiologiju Srbije
14:55–15:10	**Hirurško lečenje urođenog melanoma – prikaz slučaja** (predavanje)	**Marija Popović,** Medicinka sestra – instrumentarka, Institut za onkologiju i radiologiju Srbije
15:10–15:25	**Izolovana perfuzija ekstremiteta** (predavanje)	**Novica Radovanović,** Strukovni medicinski tehničar, Institut za onkologiju i radiologiju Srbije
15:25–15:40	**Značaj multidisciplinarne saradnje u dobijanju informisanog rezultata BRAF genetičkog testiranja za lečenje pacijenata obolelih od metastatskog melanoma** (predavanje)	**Marijana Topalović,** Strukovni medicinsko laboratorijski tehnolog, Institut za onkologiju i radiologiju Srbije
15:40–15:55	**Novine u lečenju melanoma – sestrinski aspekti** (predavanje)	**Kristina Stošić,** Master strukovna medicinska sestra, Institut za onkologiju i radiologiju Srbije
15:55–16:05	Diskusija	
16.05–16:15	**Evaluacija Simpozijuma**	
16:15–16:25	**Zaključci Simpozijuma**	
16:25–16:35	Kafe pauza	



Curiosity is the driving force of our innovation.

We know that when it comes to improving people's lives, there are always new life-changing breakthroughs we can make. That's what drives us.

www.roche.com

Roche d.o.o || Vladimira Popovića 8a || 11000 Beograd || Srbija || M-RS-00002895


AstraZeneca
Inspired by our values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.
Predstavništvo AstraZeneca UK Ltd
Milutina Milankovića 1i
Beograd - Novi Beograd
Tel: 011 3336 900
Fax: 011 3336 901
SAMO ZA STRUČNU JAVNOST
RS-6229, novembar 2024.

NOVARTIS

Let's reimagine medicine, **together**



Novartis Pharma Services Inc.
Predstavništvo Beograd
Omladinskih brigada 90a
11070 Beograd, Srbija
office.serbia@novartis.com

RS_0924_FA-11274781

svaki dan

Verzenios▼

abemaciklib

dva puta dnevno



▼ Ovaj lek je pod dodatnim praćenjem. Time se omogućava brzo otkrivanje novih bezebednosnih informacija. Zdravstveni radnici treba da prijave svaku sumnju na neželjene reakcije na ovaj lek. Za način prijavljivanja neželjenih reakcija videti odeljak 4.8. Sažetka karakteristika leka.
Pre propisivanja leka Verzenios, molimo pročitajte poslednji odobreni Sažetak karakteristika leka - Verzenios, januar 2024.

Predstavništvo Eli Lilly (Suisse) S.A.
Vladimira Popovića 38-40, 11070 Beograd, Srbija
Telefon: +381 11 6550001; Fax: +381 11 7120798

Lilly

PP-AL-RS-0111 | SEPTEMBAR 2024. | SAMO ZA STRUČNU JAVNOST



Pfizer SRB d.o.o., Trešnjinog cveta 1, 11000 Beograd, Srbija
Datum izrade: februar 2024. Oznaka materijala: PP-UNP-SRB-0162

KEYTRUDA®
(pembrolizumab)



Samo za stručnu javnost
Pre propisivanja, molimo Vas da proučite
Sažetak karakteristika leka.

MSD

Nosilac dozvole: MERCK SHARP & DOHME D.O.O.
Omladinskih brigada 90a/1400, Beograd - Novi Beograd
Broj dozvole za stavljanje leka u promet:
515-01-03916-21-001 od 23.09.2022.
Datum revizije teksta: Maj, 2024.
Režim izdavanja leka: Lek se može upotrebljavati
samo u stacionarnoj zdravstvenoj ustanovi.

RS-KEY-00554

NOTES

NOTES

NOTES

GENERAL SPONSOR

Roche

PLATINUM SPONSORS

AstraZeneca

NOVARTIS

Lilly

GOLD SPONSOR

Pfizer Oncology

SILVER SPONSOR

MSD

SPONSORS

Amicus
a Swixx BioPharma company

SANDOZ

Hemofarm
STADA GRUPA

MERCK

Family Health
YOUR PEACE OF MIND

Johnson&Johnson

BAYER

Slaviamed
PHARMACEUTICALS

SERVIER
moved by you

GENOPHARM

PHARMASWISS

B BRAUN
SHARING EXPERTISE

Conservice
IPK

ORTHOAID